Cumberland Pharma reports reduced opioid use with pain product
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the publication of a trial providing evidence that using Caldolor in multimodal pain control strategies improves postoperative pain control and reduces opioid use in patients undergoing transsphenoidal surgery. The trial was conducted at the Department of Neurosurgery, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, and was published in the Journal of Neurosurgery, March 2017.
“The United States is in the midst of an epidemic of excessive opioid use, misuse, and abuse to control chronic pain,” said AJ Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. “The more we can prevent postsurgical pain from transitioning into chronic pain, the more likely we are to decrease reliance on opioids and improve the quality of life for patients long-term. We are thrilled to add this study to the growing body of literature supporting the safety and use of Caldolor in hospitalized patients.”